On May 26, 2025, the “2025 Antibody Therapeutics Conference and the 20th Frontiers in Biomedical Sciences Conference” — jointly hosted by Academia Sinica’s Translational Medicine Research Center and the Taiwan Antibody Association (TAA) — was held in Taipei. The event brought together key players from academia and industry, including Chang Gung Memorial Hospital, Taiwan Bio-Medicine Manufacturing Corp. (TBMC), OBI Pharma, and GenomeFrontier Therapeutics, to exchange cutting-edge developments in antibody and cell-based therapies. Dr. Sareina Wu, Chief Scientific Officer of GenomeFrontier Therapeutics, was invited to present the company’s proprietary virus-free Quantum Engine platform and its first-in-class T-cell engineering system: Quantum CAR-T ( qCART™). This platform not only enables efficient generation of CAR-T cells enriched with stem cell–like memory T cells (TSCM), but also supports the development of multi-target CAR-T therapies that can overcome antigen escape and reduce relapse rates. In preclinical gastric cancer models, CAR-T cells produced via the qCART™ system achieved complete tumor elimination by Day 17, in contrast to viral vector–based CAR-T therapies, which failed to fully eliminate tumors under the same conditions. These findings highlight the significant safety and efficacy advantages of GenomeFrontier Therapeutics’s virus-free approach.
Dr. Wu also introduced GF-CART01, the company’s lead clinical candidate targeting both CD19 and CD20, designed to mitigate antigen escape and prolong T-cell persistence through the inclusion of a specific modulator. Preclinical studies have demonstrated high safety, strong efficacy, and clear dose-dependency. In February 2025, the Taiwan FDA (TFDA) granted approval to initiate a Phase I clinical trial. To tackle the unique challenges of solid tumors, GenomeFrontier Therapeutics is also developing a next-generation CAR-T therapy, GF-CART03, tailored for glioblastoma multiforme (GBM). This product incorporates a multi-target strategy and safety switch, delivered directly via neurosurgical injection. The approach addresses tumor heterogeneity, immunosuppressive microenvironments, and the complex anatomy of brain tumors. The project is being conducted in collaboration with Dr. Wei at Chang Gung Memorial Hospital, with clinical trials planned in Taiwan and expansion into the US and EU markets.
With its mission to make advanced therapies more affordable and accessible, GenomeFrontier Therapeutics continues to advance the clinical application of its virus-free Quantum Engine platform and qCART™ system, offering safer, more effective, and cost-efficient solutions for patients. With innovation at its core and patients at the center, GenomeFrontier Therapeutics is committed to setting new standards in the future of global gene and cell therapy.
For more information: https://news.gbimonthly.com/tw/article/show.php?num=77371